XOMA reports FY 2022 net loss of $17.1M; Vabysmo commercial payments begin

XOMA Royalty Corp

FY 2022 revenue $6.0M vs $38.2M in 2021; net loss $17.1M vs net income $15.8M.
Cash $57.8M at Dec 31, 2022; no debt.
Received second Vabysmo commercial payment from Roche in Feb 2023; 0.5% interest in sales.
Ebopiprant deal with Organon offers up to $378M milestones plus mid-single/low-teen royalties.
Executive Chairman Owen Hughes and CIO Brad Sitko added to lead royalty acquisition strategy.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.997

XOMA Royalty Corp reported the quarter and year ended December 31, 2022 results: revenue $1.5 million and $6.0 million, net income Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million.

Period: the quarter and year ended December 31, 2022
Revenue: $1.5 million and $6.0 million
Net income: Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million
Result: reported results

Exact text from the filing

said Brad Sitko, Chief Investment Officer of XOMA. Fourth Quarter and Full Year 2022 Financial Results Revenues for the fourth quarter and year ended December 31, 2022, were $1.5 million and $6.0 million, respectively. For the full year of 2022, XOMA’s reported revenues were related to milestone payments of $2.0 million from Rezolute, $0.8 million from Takeda,

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-065314

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.